Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of Accounting for Stock-Based Compensation

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:


	Three Months Ended
	March 31,
	2020		2019

Employee and director stock option grants:
Research and development	$	23,735	$	27,120
General and administrative		120,411		180,534
Total stock-based compensation	$	144,146	$	207,654

Schedule of Stock Options Activity

A summary of stock option activity is as follows:


				Weighted
	Number of			Average
	Shares Issuable			Remaining
	Upon Exercise	Weighted		Contracted	Aggregate
	of Outstanding	Average		Term in	Intrinsic
	Options	Exercise Price		Years	Value
Outstanding at December 31, 2019	610,714	$	6.78	8.83	$	34,750
Granted	273,750	$	2.58
Outstanding at March 31, 2020	884,464	$	5.48	8.97	$	500

Exercisable, March 31, 2020	311,799	$	10.95	8.23	$	—
Unvested, March 31, 2020	572,665	$	2.50	9.37	$	500

Schedule of Restricted Stock Grants

The following table summarizes the restricted stock grants:


		Weighted
		Average
		Grant Date		Total Grant
	Number of	Fair Value		Date Fair
	Shares	Per Share		Value
Outstanding at December 31, 2019	9,334	$	21.00	$	196,000
Vested	(9,334)	$	21.00	$	(196,000)
Outstanding at March 31, 2020	—	$	—	$	—